Title: Humanized Anti-CCR2 Antibodies... Inventors: Gregory J. LaRosa, et al.


FIG. 1A 100
ANTI-CCR5


CCR2b.L1/2

COUNTS
40

100 101 102 103 104
FL1-H


FLUORESCENCE -







Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.











Title: Humanized Anti-CCR2 Antibodies...


Inventors: Gregory J. LaRosa, et al.

























1855.1052-028 Docket No.: Title: Humanized Anti-CCR2 Antibodies...
Inventors: Gregory J. LaRosa, et al. **L**LUORESCENCE FORWARD SCATTER— MONOCYTES DATA.001 FSC-H PBS₁₀3-101 LLUORESCENCE FORWARD SCATTER— GRANULOCYTES FIG. 2B DATA.001 FL1-H PBS **L**TNOBESCENCE


1855.1052-028 Docket No.:

Title: Humanized Anti-CCR2 Antibodies...

Gregory J. LaRosa, et al. Inventors:










1855.1052-028 Docket No.:

Title: Humanized Anti-CCR2 Antibodies...

Gregory J. LaRosa, et al. Inventors:










1855.1052-028 Docket No.:


Title: Humanized Anti-CCR2 Antibodies...


Gregory J. LaRosa, et al. Inventors:















1855.1052-028 Docket No.:

Title: Humanized Anti-CCR2 Antibodies... Gregory J. LaRosa, et al.


Inventors:


1.9284 ΥN ۷ ۷ Error 2.6422 0.15131 0.00062521 1C6 (anti CXCR3) 109 (µg/mL) ID9 (anti CCR2b) 105.63 11.518 1.0185 Value 0.9948 280.01 0.0037891 chisq Bmax Bmin œ 1050 Ξ




Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.







Title: Humanized Anti-CCR2 Antibodies... Inventors: Gregory J. LaRosa, *et al.*

1 DVVMTQTPLT LSVTVGHPAS ISC**KSSQSLL DSDGKTFLN**W LLQRPGQSPK 51 RLIY**LVSKLD S**GVPDRFTGS GSGTDFTLKI SRVEAEDLGV YYC**WQGTHFP**

101

YTFGGGTKLE IK

Figure 7

Title: Humanized Anti-CCR2 Antibodies... Inventors:

Gregory J. LaRosa, et al.

- EVQLVESGGG LVQPKGSLKL SCAASGFSFN **AYAMN**WVRQA PGKGLEWVA**R**
- 51 IRTKNNNYAT YYADSVKDRY TISRDDSESM LFLQMNNLKT EDTAMYYCVT
- 101 **FYGNGV**WGTG TTVTVSS

Figure 8

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.

Chothia Canonical Classes

L1 (16 amino acids) = Class 4

Key residues: 2(V), 25(SA), 29(L), 33(L), 71(F)

L2 (7 amino acids) = Class 1

Key residues: 48(IV), 51(AT), 52(ST), 64(G)

L3 (9 amino acids) = Class 1

Key residues: 90(QNH), 95(P)

Martin Canonical Classes

L1 (16 amino acids) = Class 4/16A

Key residues: 2(V), 4(ML), 23(C), 25(SSP), 26(SN),

27(Q), 29(LI), 30A(HL), 30B(S), 30C(NDS), 30D(G), 32(YS), 33(LF), 34(HEN), 35(W), 51(V), 71(F), 88(C),

90(Q), 92(TS), 93(H)

L2 (7 amino acids) = Class 1/7A

Key residues: 23(C)

L3 (9 amino acids) = Class 1/9A

Key residues: 2(IVL), 3(VQLE), 4(ML),

28(SNDTE), 30(DYLVISNFGHT), 31(SNTKG), 32(FYNAHSR), 33(MLVIF), 88(C), 89(QSGFL), 90(QNH), 91(NFGSRDHTYV),

92(NYWTSRQHAD), 93(ENGHTSRAQHAD),

94(DYTVLHNNIWPS), 95(P), 96(PLYRIWF), 97(T), 98(F)

Title: Humanized Anti-CCR2 Antibodies...

Inventors: Gregory J. LaRosa, et al.

Chothia Canonical Classes

H1 (5 amino acids) = Class 1

Key residues: 24(AVG), 26(G), 27(FY)

H2 (19 amino acids) = Class 4

Key residues: 54(S), 55(Y), 71(R)

Martin Canonical Classes

H1 (5 amino acids) = Class 1/10A

Key residues: 2(VIG), 4(LG), 20(LIMV), 22(C),

24(TAGVS), 26(G), 29(IFLS), 32(IHYFTNCED), 33(AWGTLV), 34(IVMW), 35(HENQSYT), 36(W),

48(IMLV), 51(LIVTSN),

69(ILFMV), 78(ALVYF), 80(LM),

90(YF), 92(C), 94(RKGSNH),

102(YHVISDG).

H2 (19 amino acids) = Class ?/12B

Key residues: 47(W), 50(RQ), 51(I), 59(Y), 69(I),

71(R), 78(LV)

Figure 10

Figure II

CDRs	==H]================================
Kabat Numbers 1234	1 1 2 3 3 4 5 5 6 7 8901234567890123456789012A5678901234567890123456789012345678901234567890123456789012345678901234567890123
1D9 EVQI	EVQLVESGGGLVQPKGSLKLSCAASGFSFNAYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSESMLFLQMNNLKTEDTAMYYCVTFYGNGVWGTGTTVTVSS
4B4'CL V _H	4B4'CL V _H
1D9RH _A V _H EVQI	109RH _A V _H EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS
1D9RH _B V _H EVQI	1D9RH _b V _H EVQLVESGGGLVKPGGSLRLSCAASGF SFN AYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS
1D9RH _C V _H EVQI	1D9RHc V# EVQLVESGGGLVKPGGSLRLSCAASGFSFNAYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS
1D9RH _D V _H EVQI	1D9RH _b V _H EVQLVESGGGLVKPGGSLRLSCAASG FSFN AYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSKNTLYLQMNSLKTEDTAVYYCVTFYGNGVWGQGTLVTVSS
Key	
1D9 V _H	Mouse 1D9 V _H region.
$4B4$ °CL V_H	Chosen human framework acceptor V _H region sequence with mismatches to the 1D9 V _H region highlighted.
$1D9RH_A$ V_H	CDR grafted 1D9 V _H region, with no back mutations.
· 1D9RH _B V _H	CDR grafted 1D9 V _H region, with back mutations at T28S and S30N.
$1D9RH_{C}V_{H}$	CDR grafted 1D9 V _H region, with back mutations at T28S, S30N, G49A and F67Y.
$1D9RH_DV_H$	CDR grafted 1D9 V _H region, with back mutations at T28S, S30N, G49A, F67Y and T93V

Figure 12

1D9 $V_{\rm K}$	114	DVVMTQTPLTLSVTVGHPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFP
70/3	76	I.Q.
70/2	82	S
V-IB	16	$\dots S. P. SL. DQ. \dots R. \dots VH. \ N.N. Y. Y. Y. K. \dots L. \dots R. NRF. \dots S. \dots \dots F.F. \dots V.$
V-1C	7.5	S
V-1A/K5.1/K5.1	75	:
V-1C/V1A5/K1A5	74	LS.P.SL.DQRIVH. N.N.Y.E.YKLKNRFSFS.V.
K18.1	73 ·	.AS.P.SL.DQR.N.EN. N.N.YYKQLRNRFLSF.L.VV.
1F	71	:
24A	89	$. 1 \dots AAFSNP \dots L. TS \dots R. K \dots H. S. N. Y. Y. F. K \dots QL \dots YI. N. A \dots S \dots \dots R \dots \dots V \dots \dots M \dots LEY.$
167/24	29	.I.IDE.SNPS.ESVRKYKYFQLM.TRASSEKVQ.LVEY.
24B	99	$. I.\dots. AAFSNP L.TS.\dots.RKH. \ N.I.Y.Y.YK.\dots.QLQM.N.A.\dotsSS.\dotsR.\dotsV.\dots.A.NLEL.$

1D9 V _H	117	EVQLVESGGGLVQPKGSLKLSCAASGFSFNAYAMN	EVQLVESGGGLVQFKGSLKLSCAASGFSFNAYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSESMLFLQMNNLKTEDTAMYYCVTF
MRL-RF24BG	98	VWWRMTTT.	S.SSFQYI-
V(H)22.1	70	K.EGMVT.SN.W.S	S.EQL.SDHEG.FK.SVYRAGITG-
V11/pBV19B4	99	K	PALGFN.A.G.T.E.SAG.FN.Q.I.YT.RAS.TAR-
Vh7183 (Vh69.1)	99	K	S.E.RT.SSGGSYPG.FNAKNT.YSSSTR-
VH10-19	65	D.K	T.E.RT.SSGGSYPG.FNAKNT.YSSSTR-
VHE4-psi	65	.L	:
V(H)50.1	65	K	T.E.RY.SNGGGSP.TG.FNAKNT.YSRSAR-
V3	65	K	
V1/pBV132	64	KGRTT.SDFY.E	PRI.AS.N.A.D.T.E.SAG.FIVT.Q.I.YA.RAIAR-
VH283	64		
V(H)37.1	63		T.E.RT.SGGGSYPG.FNAKNN.YSS.RSLAR-
V13	61	K.MGARET.TD.Y.S	I.R.SPL.I.N.A.G.T.E.SAG.FN.QNI.YT.RA.AS.TAKD
V-H 441/V441	59	K.LGD.SR.W.S	
68- <u>5</u> N	59		T.D.RLT.NSGGSPG.FNAKNT.YSSSAR-
76-1BG/VH7183.9	58	K.GT.SSS	
61-1P	58	T.SSFG.H	EY.SSGSSTIT.G.FNPKNTTS.RSAR-
57-1M/VH7183.12	58	T.SSS	T.E.RS.SSGGSPG.FNARNI.YSS.RSAR-
V(H)55	26	K.LGND.SR.W.S	.AQIGE.NPGSSTIN.TP.LKFINAKNT.YSKVRSLAR-
VH7183.13	55	T.SS.T.S	T.E.RY.SNGGGSP.TG.FNAKNT.YSSSAR-

e	
2	
=	
ā	
=	
\sim	
۳,	
$\overline{}$	
.2	
⋖	
\simeq	
.=	
Ħ	

Maille	a a	SCSCCCsesscscscscscscscscscscscscsccCCCccccccsSCCCCCCCC
		1 2 3 4 5 6 7 8 9 0 0 1234567890123456789012345678901234567890123456789012345678901234567890123456789012345647890123456489012345678901234564789012345648901234567890123456478901234564789012345648901234567890123456489012345678901234564890123456789012345678901234564890123466489012346489012346648901
1D9 V _K	100.0	DVVMTQTPLTLSVTVGHPASISCKSSQSLLDS-DGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPYTFGGGTKLEI-K
036521	90.4	. IQLsI.Q
99'II	78.8	R.D
RPMI6410	78.8	RVYN.YFQRKNRS
I-IMZ	78.8	$\dots R. L. V. \dots N. Y. F. \dots R. \dots QL. SR \dots S. \dots \dots V. \dots W.$
VL Clone 54	78.1	$. I \dots S \dots S \dots P \dots L \dots Q \dots \dots R \dots$
HF-21/28	79.3	S.S.P.I.QRVHN.YFQRK.NRSVMW. FQ.R
SpA2-08	6.77	RLD.Y. YQR. K.NRS
II.30	77.9	
HUNVK	77.9	RVFN.YFQRKNRSV.IIMA.W.
0-81	75.7	RVHN.Y. FQR.NRSV.LM.H.WSP
ToP309	74.8	
ToP218	74.8	
SpA3-02	76.1	RVYN.YFQRKNRSVW.
11.37	75.2	TVYTIYFQRFKNRSVAIMW.
CUM	73.9	R
VL Clone 51	74.6	R. RG. VH N. Y FQ R KNR S A V M. SI.W.
II.20	75.2	$\dots N.YFQ.\dots RKNR.\dots S.S.\dotsT.\dotsV.I.\dots MRW.$

Docket No.:	1855.1052-028
Title: Humar	nized Anti-CCR2 Antibodies
Inventors:	Gregory J. LaRosa, et al.
	•

1																	
L3 Class	_	O 1	? Same	Same	Same		Same	Same	<i>د</i> ٠	٠	<i>د</i>	Same	Same	Same	Same		Same
L2 Class	-	Same	Same Same	Same	Same	Same	Same	Same	Same	Same	Same	Same	Same	Same	Same		Same
L1 Class	4	Same	Same Same	ć	Same	٠.	Same	Same	Same	¿	٠.	٠.	Same	3	ċ		?
L3 Len	6	Same	Same Same	Same	Same	Same	Same	Same	10	10	10	Same	Same	Same	Same		Same
L2 Len	7	Same	Same Same	Same	Same	Same	Same		Same	Same	Same	Same	Same	Same	Same		Same
L1 LenL2 LenL3 Len L1 Clas	16	Same	Same Same		Same	Same	Same	Same	Same	Same	Same	Same	Same		Same		Same
Closest Human Germline Gene		DPK19-A1+ DPK18-A17+	DPK18-A17+ DPK18-A17+	DPK18-A17+	DPK18-A17+	DPK18-A17+	DPK18-A17+	DPK18-A17+	DPK18-A17+	DPK12-A2+	DPK12-A2+	DPK18-A17+	DPK18-A17+	DPK36-Chr22 4	DPK18-A17+		DPK18-A17+
J Chain	14	13	12	12	12	12	12	12	12	12	12	17	12	12	12		12
V K	100	06	62	79	78	11	11	11	11	9/	9/	9/	9/	75	75		75
Vernier	4	13	13	13	13	13	12	12	12	12	12	12	12	12	12		12
FR Near CDR	33	31	98	30	30	30	30	30	30	53	59	53	59	29	29		29
Core FR	09	56	25 27	52	52	51	51	51	51	51	51	51	51	20	20		20
FR Surface	22	19	<u>8</u> 8	18	18	18	18	18	18	18	18	18	18	18	18		18
FR	82	75	69	89	89	89	89	89	89	89	89	89	89	89	<i>L</i> 9		<i>L</i> 9
Kabat CDR	32	28	22	21	21	21	21	21	21	20	20	20	20	20	20		20
Core	82	76	99	99	99	92	92	92	65	64	64	63	63	63	62		62
Surface Core Kabat CDR	30	27	25 25	25	24	24	24	24	24	24	24	24	24	24	24		23
a	100.0	90.4	78.8 78.8	78.1	79.3	77.9	77.9	77.9	75.7	74.8	74.8	76.1	75.2	73.9	74.6		75.2
Name	$1D9 V_K$	036521 II.66	KPM16410 ZM1-1	VL clone 54	HF-21/28	SpA2-08	II.30	HUNVK	0-81	ToP309	ToP218	SpA3-02	II.37	CUM	VL clone	51	11.20

Figure 16

Figure 17A

Маше	a	2382323222 $288232322222323232323232323232323232323$
		1 1 2 3 4 5 6 7 8 9 0 1 1 1 2 2 3 4 5 5 6 7 8 9 0 1 1 1 2 3456789012345678901234567890123456789012345678901234567890123456789012345678901234567890123456789012345678901234567890123 4567890
ID9 V _H	100.0	EVQLVESGGGLVQPKGSLKLSCAASGFSFNAYAMNWVRQAPGKGLEWVARIRTKNNNYATYYADSVKDRYTISRDDSESMLFLQMNNLKTEDTAMYYCVTFYGNGVWGTGTTVTVSS
030094 N51P8	67.7	G R I SD V D A I TE A G F MAS S S I CVRTDCSCHRC HGMD O
IW2-91	67.5	T.SDHY.DG. N.A.S.T.E.A.L.G.FNS.YSV. ARAETDRGYYYYH
H2-46	66.7	T.SGS. HSGS.A.SA.AG.FKNTAYSVTRWVLGRGSEGHY
039158	72.2	SSAAAG.FKNTAYSVASGSYLK
038064	9.59	
038062	64.6	$\dots L \dots \dots G \dots R \dots \dots \dots \dots \dots SA \dots SG \dots SA \dots GGS \dots \dots G \dots G \dots \dots G \dots \dots G \dots \dots \dots \dots \dots \dots$
32.B9	64.6	$\dots G.QR.\dots G.QR.\dots G.QR.\dots G.V.S$
038062	64.6	:
034514	8.69	
990860	65.3	IGRT.SSSSG.SG-~SGGSEG.FN.KNT.YS.RAVAND.YGSGRYFTYAT DQ
035365	62.9	L
Hb-5	69.2	$Q_1\ldots Q_2\ldots Q_R.R.\ldots T.SN\ldots S \qquadSA.SGSGGS\ldots G.F\ldots NAKNT.Y\ldots S.\ldots V T.YD \qquad GMDKMI$
4G12	64.8	LGRT.STSSA.SGSGGSG.FN.KNT.YS.RAVAKAVVRGVIS YYYYGMDQ
VH Clone 39		
040094	62.5	K.GRI.SIGW.SGKS.IDGGIIDEPG.FKNTSVI.ALTRYFFDSSGYPH FDHHL
VH Clone 18	63.0	

Amino Acid Sequence

വ
ਹੁ
_
7
\simeq
₽
Ь
வ
Š
•
~
.=
Έ.
⋖;
_
9
₽.
:=
=
-
<
7

Name	A	All	Surface Core	Core	Kabat CDR	FR	FR Surface	Core FR	FR Near CDR	Vernier	$V_{\rm H}$	Vernier V _H J Chain	Closest Human Germline Gene	H1 Size	H2 Size	H3 Size	H1 Class	H2 Class
1D9 V _H	100.0	117	29	84	30	87	21	99	30	16	100	17		. 2	19	9		4
030094	67.7	98	19	<i>L</i> 9	15	72	17	57	26	12	75	13	DP-29-122+		Same	16	Same	Same
N51P8	68.3	98	81	99	15	72	16	57	25	12	75	13	DP-29-122+		Same	15	ڼ	Same
IW2-91	67.5	85	18	65	15	72	16	99	25	12	75	12	DP-29-122+	Same	Same	15	Same	Same
H2-46	2.99	84	18	65	15	72	16	99	25	12	75	12	DP-29-122+		Same	15	Same	Same
039158	72.2	83	17	64	15	71	15	99	25	12	74	12	DP-29-122+					
038064	9.59	82	17	64	14	71	15	99	25		74	12	VH26Rabbitts+					
038062	64.6	82	17	63	14	71	15	99	25	=	73	12	VH26Rabbitts+					
32.B9	64.6	82	17	63	14	71	15	99	25	=	72	12	VH26Rabbitts+	Same	17	16	Same	3
038062	64.6	82	17	63	14	71	15	99	25	Ξ	72	12	VH26Rabbitts+					
034514	8.69	81	17	63	14	70	15	99	25	Ξ	72	12	VH26Rabbitts+					
038066	65.3	81	91	63	14	70	15	55	25	=======================================	71	12	VH26Rabbitts+					
035365	65.9	81	16	63	14	70	15	55	25	Ξ	71	12	VH26Rabbitts+					

H2 Class	ကက	n	<i>w w e- e- w</i>	c. c.
H1 Class	Same Same	Same	Same Same Same Same	Same Same
H3 Size	11	18	10 15 13 12	8
H2 Size	17	17	17 17 Same Same 17	Same Same
H1 Size	Same	Same	Same Same Same Same	Same Same
Closest Human Germline Gene	VH26Rabbitts+ VH26Rabbitts+ VH26Rabbitts+	LSG3.1 VH26Rabbitts+	DP-31-V39P+ VH26Rabbitts+ LSG3.1 LSG3.1 VH26Rabbitts+	LSG3.1 LSG3.1
J Chain	12 12 12	12	=======================================	==
$V_{\rm H}$	71 71 71 71	71	11 11 11 11	71
Vernier	===	= =	=====	= =
FR Near CDR	25 25 25	25 25	25 25 25 25 25	25 25
Core FR	55 55 55	55 55	55 55 55 55 55	55
FR Surface	15 15 14	14 4	4 4 4 4 4	14 14
FR	69	69	69	89
Kabat CDR	4	14 13	22222	13. 13
Core	63 63	63	63 63 63 64	62
All Surface Core	16 16 16	16	16 16 16 16	16
All	81 81 80	80	80 80 80 80 80	80
a	69.2 64.8 66.7	62.5 63.0	67.2 64.5 64.5 65.0 66.1	67.2 65.0
Name	Hb-5 4G12 VH clone	99 040094 VH clone 18	UB1-24 029764 IW2-105 UB1-17	41 4B4'CL M26

Kabat	#	FR or CDR	Mouse 1D9 V _K	Mouse к-II	Human к-П	Human Acceptor HF-21/28 (005056)	Surface or Core	1D9 RK _A	1D9 RK _B	Commen
1	1	FR1	D	D*	D		S	D	D	
2	2	1101	V	v	I*	<u> </u>	c	1 V	V	
3	3	 	v	v	V*		S	V	V	
4	4		M	M	M		c	M	M	
5	5	 	T	T*	T		Č	T	T	
6	6	·····	Ô	0*	Q		č	T o	Q	
7	7		T	T	S	S	S	Š	S	
		ļ			_1			_1	1	
8	8	ļ	P	P	P		С	P	P	
9	9		L	L	L		s	L	L	
10	10		T	S	S	S	С	<u> </u>	<u>S</u>	ļ
11	11	<u> </u>	L	L	L*		С	L	L	
12	12		S	P	P	R	С	<u>P</u>	<u>P</u>	ļ
13	13		V	V*	V*		С	V	V	
14	14		T	S	T		С	T	T	
15	15		V	L	P	L	s	<u>L</u>	<u>L</u>	ļ
16	16		G	G	G		С	G	G	
17	17		Н	D	E	Q	С	Q	Q	
18	18		P	Q	P		'S	P	P	
19	19		A	A	A		С	A	A	
29	20		S	S*	S		С	S	S	ļ. <u> </u>
21	21		I	I*	I		С	I.	I	ļ
22	22		S	S*	S*		C	S	S	
23	23	FR1	C	С	С		С	C	С	ļ
24	24	CDR1	K	R	R	R	S	K	K	
25	25		S	S*	S*		С	S	S	ļ
26	26		S	S*	S		S	S	S	ļ
27	27		Q	Q	Q		S	Q	Q	
27A	28		S	S	S		S	S	S	
27B	29		L	L	L		С	L	L	
27C	30		L	V	L	V	S	L	L	.
27D	31		D	Н	Н	Н	С	D	D	
27E	32		S	S	S		S	S	S	
27F	ļ		I		x			<u> </u>	-	ļ
28	33		D	N	D		S	D	D	L
29	34		G	G*	G		С	G	G	<u> </u>
30	35		K	N	N	N	С	K	K	
31	36		T	T	N		С	T	T	
32	37		F	Y*	Y	Y	с	F	F	
33	38		L	L*	L		С	L	L	
34	39	CDR1	N	E	N		С	N	N	
35	40	FR2	W	W	W		С	W	W	
36	41		L	Y	Y	F	С	F	L	Δ1

Figure 19A

Kabat	#	FR or CDR	Mouse 1D9 V _K	Mouse κ-II	Human ĸ-II	Human Acceptor HF-21/28 (005056)	Surface or Core		1D9 RK _A	1D9 RK _B	Comment
37	42		L	L	\dashv $_{\rm L}$	Q	С		Q	L	Δ2
38	43		Q	Q*	Q		С		Q	Q	
39	44		R	K	K		С		R	R	
48	45		P	P*	P		S		P	P	
41	46		G	G*	C		S		G	G	
42	47		D	Q	Q		С		Q	Q	
43	48		S	S*	S		С		S	S	
44	49		P	P*	F		С		P	P	
45	50		K	K	Q	R	С		<u>R</u>	<u>R</u>	
46	51		R	L	L		С		R	R	
47	52		L	L*	L		C		L	L	ļ <u>.</u>
48	53	EE -	I	I*	I		C		I	I	<u> </u>
49	54	FR2	Y	Y	Y		С		Y	Y	
5Ω 51	55	CDR2	L	K	L	V	С		L V	L	
51	56	 	V S	V S	V S	K	c		S	S	<u> </u>
52 53	57		K	N	N N	-	c c		K S	K	
54	59		L	R	R	N	c		L	L	-
55	60		D	F	A	R	c		D	D	
56	61	CDR2	S	S*	S	K	s		S	S	
57	62	FR3	G	G	G	l	S		G	G	
58	63	113	, V	V	V	-	C		$\frac{\sigma}{V}$	V	+
59	64		P	P	P		Č		P	P	
60	65		D	D*	D		S		D	D	
61	66		R	R	R		Č		R	R	
62	67		F	F*	F	-	c		F	P	
63	68		T	S	S	S	С		<u>s</u>	<u>s</u>	
64	69		G	G*	G		С		G	G	
65	70		S	S*	S		С		S	S	
66	71		G	G*	G		С		G	G	
67	72		S	S*	S		S		S	S	
68	73		G	G*	G		С		G	G	
69	74		T	T*	T		С		T	T	
70	75		D	D*	D		С		D	D	
71	76		L	F*	F		С		F	F	
72	77		T	T*	Т		С		T	T	ļ
73	78	<u> </u>	L	L	L		С	Ш	L	L	
74	79		K	K	K		С	Ш	K	K	
75	80	ļ	I	I	I	ļ	С		I	I	
76 ·	81		S	S	S	 	С	Ш	S	S	
77	82	 	R	R*	R		S	Н	R V	R V	
78	83		V	V	V	 	С	<u> </u>	L	E	
79	84		E	E	L		S	-			
80	85		A E	A* E*	A E		C	\vdash	A L	A E	
81	86	 	D	D*	D	-	s c	\vdash	D	D	· · · · ·
82	87	+	L	L L	V	V		H	$\frac{D}{V}$	V	-
83	88	+ + -	G	G*	G	 	С	\vdash	G	G	-
84	89		V	V	V		С	\vdash	V	V	1
85	90		Y	Y*	Y		C	\vdash	Y	Y	
86	91		Y		Y	-	C C		Y	Y	
87 88	92	FR3	C	Y C	C		C	\vdash	C	C	-

Figure 19B

Kabat	#	FR CD		Mouse 1D9 V _K	Mouse к-II	Human κ-II	Human Acceptor HF-21/28 (005056)	Surface or Core	1D9 RK _A	1D9 RK _B	Comment
89	94	CD	R3	W	F	M		c	\mathbf{w}	w	
90	95		,	Q	Q*	Q	M	С	Q	Q	
91	96			G	G	Α		С	G	G	
92	97			Т	Т	L		С	Т	T	
93	98			Н	Н	Q		С	Н	H	
94	99			F	V	х		s	F	F	
95	100			P	P*	F	W	С	P	P	
95A				-	P	R				-	
95B				• -	-	 -				-	
95C				-	-	 _				-	
95D				-	-	-		<u> </u>		-	
95E				-	-	_			-		
95F				-	-	 -				-	
96	101			Y	Y	 x	-	С	Y	Y	
97	102	CD	R3	T	T*	 T	F	С	Т	Т	
98	103	FR	4	F	F*	F		С	F	F	
99	104			G	G	G		С	G	G	
100	105			G	G	Q	Q	С	Q	<u>G</u>	
101	100			G	G	G		С	G	G	
102	106			T	Т	T		С	T	T	
103	107			K	K*	K	R	s	<u>R</u>	· <u>R</u>	
104	108			L	L	V		С	L	L	
105	109			Е	Е	Е		S	Е	E	
106	110			I	I	I		S	1	I	
106A				-	-	-			-	-	
107	111	FR	4	K	K*	K	-	S	K	K	

Figure 19C

Kabat	#	FR or CDR	Mouse 1D9 V _H	Mouse IIIc	Human III	Human Acceptor 4B4'CL (000490)	Surface Or Core		1D9 RH _A	1D9 RH _B	Comment
		701									
1	1	FRI	E	E*	E		S		Е	Е	
2	2		V	V	V		С		V	V	
3	3		Q	K*	Q		s		Q	Q	
4	4		L	E*	L*		С		L	L	
5	5		V	E	V		S		V	V	
6	6		E	E	L		С		E	Е	
7	7		S	S	S*		С		S	S	
8	8		G	G	.G*		С		G	G	
9	9		G	G	G*		С		G	G	
10	10		G	G*	G		С		G	G	
11	11		L	L	L		S		L	L	
12	12		V	V*	V		С		V	V	
13	13		Q	Q	Q	K	S		<u>K</u>	<u>K</u>	
14	14		P	P	P*		С		P	P	
15	15		K	G	G*	G	S		G	<u>G</u>	
16	16		G	G	G		, S		G	G	
17	17		S	S	S*		С		S	S	
18	18		L	M*	L*		С		L	L	
19	19		K	K*	R	R	С		<u>R</u>	<u>R</u>	
20	20		L	L	L		С		Е	L	
21	21		S	S	S*		С		S	S	
22 ·	22	<u> </u>	С	С	C*		C		С	C	
23	23		A	V	A		С		A	A	
24	24		A	Α	A		C		Α	A	
25	25		S	S	S*		C.		S	S	
26	26		G	G	G		С		G	G	
27	27		F	F	F*		L		E	F	
28	28	<u> </u>	S	T*	Т	T	C		T	S	Δ1
29	29		F	F*	F		С		F	F	
30	30	FR1	N	S	S	S	S		S	N	Δ2
31	31	CDR1	A	N	S	N	С		A	A	
32	32	1	Υ	Y	Y	Α	S		Y	Y	
33	33	i	A	T	A	W	S		A	A	1
34	34	1	M	M	М		С		M	M	
35	35		N	N	S	S	С	. 11	N	N	
35a		i .		-	-		С		-	•	
35b		CDR1	-	-	-		С		-	•	

Figure 20A

1855.1052-028 Docket No.:

Kabat	#	FR or CDR	Mouse 1D9 V _H	Mouse IIIc	Human III	Human Acceptor 4B4'CL (000490)	Surf- ace Or Core	1D9 RH _A	1D9 RH _B	Comment
36	36	FR2	W	w	w*		С	w	w	
37	37		V	V	V*		С	V	V	100000
39	38		R	R	R*		С	R	R	
39	39		Q	Q	Q*		С	Q	Q	
40	40		A	S	A		С	Α	Α	
41	41		P	P	P		S	P	P	
42	42		G	E	G*		S	G	G	
43	43		K	K	K		s	K	K	
44	44		G	G	G		С	G	G	
45	45		L	L	L*		C	L	L	
46	46		E	E*	E		С	E	Е	
47	47		W	W	W*		С	W	W	
48	48		V	V*	V*		C	V	V	ļ
49	49	FR2	Α	A	S	G	С	<u>G</u>	<u>G</u>	
50	50	CDR2	R	Е	V		С	R	R	
51	51		I	I	I		С	I	I	
52	52		R	R	S	K	S	R	R	
52a	53		T	L	G	S	s	T	T	
52b	54		K	K	K*		S	K	K	
52c	55		N	S	Т	Т	С	N	N	
53	56		N	Н	D	D		N	N	
54	57		. N	N	G	G		N	N	
55	58		Y	Y	G	G	ļ	Y	Y	
56	59		<u> </u>	A	S	T	S	<u> </u>	A	
57	60		T	T	T		С	T	T	
58	61		Y	H	Y	D	С	Y	Y	
59	62	-	Y	Y	Y		С	Y	Y	
60	63		A	A	A		С	A	A	
61	64		Q S	E S	S	A P	S	D S	S	
63	66	 	V	- 3 V	V*	r	s c	- S	V	
64	67	 	K K	K	K		S	K	K	-
65	68	CDR2	D D	G	G*	G	S		D	
66	69	FR3	R	R	R*	<u> </u>	C	R	R	-
67	70	110	Y	P	F*	F	C	F	E	
68	71	 	T	T	T	<u> </u>	C	T	Ť	
69	72	 	Ī	I*	1*		c	Ī	i	
70	73	1 1	S	S	S*		S	S	S	
71	74		R	R	R*		С	R	R	1
72	75		D	D	D		С	D	D	
73	76		D	D	N		С	D	D	
74	77		S	S	.S		s	S	S	
75	78		E	K	K	K	S	<u>K</u>	<u>K</u>	
76	79		S	S	N	N	S	N	N	
77	80		М	S	T	T	С	T	Ī	
78	81		L	V	L		С	L	L	
79	82		F	Y	Y	Y	· c	Y	<u>Y</u>	

Figure 20B

Kabat	#	FR or CDR	Mouse 1D9 V _H	Mouse IIIc	Human III	Human Acceptor 4B4'CL (000490)	Surface Or Core	1D9 RH _A	1D9 RH _B	Comment
81	84		Q	Q*			c	Q	Q	
82	85		M	M	M*		c	$\frac{1}{M}$	M	
82a	86		N	N	N		S	N	N	
82b	87	T	N	N	S	S	s	S	S	
82c	88	l i	L	L	L*		С	L	L	
83	89	T	K	R	R		s	K	K	
84	90		T	A	Α		С	T	T	
85	91	T	Е	Е	E		s	E	Е	
86	92		D	D	D		С	D	D	
87	93		T	T	T		С	T	T	
88	94		A	G	A*		С	Α	Α	
89	95	T	M	I	V	V	С	<u>V</u>	V	
90	96		Y	Y	Y*		c	Y	Y	
91	97		Y	Y	Y*		G	Y	Y	
92	98	T	С	C*	C*		C	С	С	
93	99		V	T	Α	Ť	С	I	T	
94	100	FR3	T	T	. R		С	T	T	
95	101	CDR3	F	G	G	D	С	F	F	
96	102		Y	F	R	S	С	Y	Y	
97	103		G		x	L	S	G	G	i
96	104		N	-	G	Р	С	N	N	†
99	10.				х	P	С	-	-	·
100		i		-	S	Н	С	-		
100 a	 			-	L		C	<u> </u>	-	
100 b			-	-	S		С	<u> </u>	-	
100 c					G			-	-	į .
100 d			-	- 1	-			-	-	
100 e			-	1 - 1	Y			-	-	
100 f				-	· Y			i -	-	
100 g	1		-		Y			-		
100 h			-		Y				-	
100 I			-		Н		1	-	-	
100 ј			-		Y			٦ -	-	
100 k			-	F	F		С	<u> </u>	-	
101	105		G	A	Q	R	С	G	G	
102	106	CDR3	v	Y	Y		С	v	V	
103	107	FR4	W	w	W*		С	W	W	
104	108		G	G	G*		С	G	G	
105	109		T	Q	Q	Q	S	Q	Q	
106	110		G	Ğ	G*		С	G	G	
107	111		T	Т	T*		С	T	Т	
108	112	T	T	L	L	L	C	<u>L</u>	<u>L</u>	
109	113		V	V	V* ·		С	V	V	
110	114	T	T	T	T*		С	Т	Т	
111	115		V	V*	V*		1	V	V	
112	116		S	S	S*	1		S	S	
113	117	FR4	S	S	S*			S	S	
				- 31						
				1 1						

Figure 20C

Inventors:

100		200		300	=	400
ATGGACTTCGGGTTAAACTTGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCGATTGTGAGGTTGTTGTTGAGTCTGGAGGAGGAGGATTGGTGCAGCCTA	leader <	AAGGGTCATIGAAACICTCATGIGCAGCCICTGGATICAGCTICAATGCCTACGCCATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGITTGGAATGGGT TICCCAGTAACTTIGAGAGTACACGTCGGAGACCTAAGTCGAAGTTACGGATGCGGTACTTGACCCAGGCGGTCCGAGGTTTCCCAAACCTTACCCA	KGSLKLSCAASGFSFNAYAMNWVROAPGKGLEWV	TGCTCGCATAAGAACTAAAAAAAATAATTATGCAACATATTATGCCGATTCAGTGAAAGACAGATACACCCATCTCCAGAGATGATTCAGAAAGTATGCTC ACGAGCGTATTCTTGATTATTAATACGTTGTATAATACGGCTAAGTCACTTTCTGTCTATGTGGTGGTGTCTTACTAAGTCTTTCAAGAG	A R I R T K N N Y A T Y Y A D S V K D R Y T I S R D D S E S M L	TITCIGCAAATGAACAACTIGAAAACTGAGGACACAGCCATGTATTACTGTGTGTGACCTTTTACGGTAACGGTGTCTGGGGCACAGGGACCACGGTCACCG AAAGACGTTTACTTGTTGAACTTTTGACTCCTGTGTCGGTACATAATGACACACTGGAAAATGCCATTGCCAGAGACCCCGTGTCCTGGTGCCAGTGGC

Figure 21

z

TCTCCTCAGCCAAAACAACAGCCCCATCCGTCTATCCCCTGGT
AGAGGAGTCGGTTTTGTTGTCGGGGTAGGCAGATAGGGGACCA

z

variable < /r>
V S S A K T T

Title: Inventors:

Docket No.:

Gregory J. LaRosa, et al.

9 200 300 400 constant ACCCAGCCTCCATCTCTTGCAAGTCAAGTCAGGCCTCTTAGATAGTGATGGAAAGACATTTTTGAATTGGTTGTTACAGAGGCCAGGCCAGTCTCCAAA GCGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGGGTCCCTGACAGGTTCACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCAGCAGAGTG TACTTCAACGGACAATCCGACAACCACGAGGACCTAAGCCCTCTGTTAGCCGCTACAACACTACTGGGTCTGAGGTGAGGTGAAACAGCCAATGGCAACCTG TGGGTCGGAGGTAGAGAACGTTCAGTTCAGTCTCGGAGAATCTATCACTTTCTGTAAAAACTTAACGAACAATGTCTCCGGTCCGGTCAGAGGTTT CGCGGATTAGATAGACCACAGATTTGACCTGAGACCTCAGGGACTGTCCAAGTGACCGTCACCTAGTCCCTGTCTAAAGTGTGACTTTTAGTCGTCTCAC CTCCGACTCCTAAACCCTCAAATAATAACGACCGTTCCATGTGTAAAAGGCATGTGCAAGCCTCCCCCTGGTTCGACCTTTATTTTGCCCGACTACGAC variable 0 z V V M T variable <u>-</u>. × 0 9 ی 0 <u>~</u> — Н S leader 0 S 0 က 0 S ဟ ٩ I

I Iga

CACCAACTGTATCCATCTTCCCACCA GTGGTTGACATAGGTAGAAGGGTGGT

۷

Figure 22

1855.1052-028 Docket No .: Humanized Anti-CCR2 Antibodies... Gregory J. LaRosa, et al. Inventors: <u> 2</u>0 Õ Ō AGACAGATTCACCATCTCCAGAGATGATTCAAAAACACGCTCTATCTGCAAATGAACAGCTTGAAAACTGAGGACACAGCCGTGTATTACTGTACCACC ICTGICIAAGTGGTAGAGGICTCTACTAAGTTITTGTGCGAGATAGACGTTTACTTGTCGAACTTTTGACTCCTGTGTCGGCACATAATGACATGGTGG GAGGIGCAATIGGIIGAGICIGGAGGAGIIGGIGAAGCCIGGGGGGICATIGAGACICICAIGIGCAGCCICIGGAIICACITICAGIGCCIACGCCA ACTIGACCCAGGCGGICCGAGGICCITICCCAAACCITACCCAACCGGCGIATICITGAITITIATIAATACGIIGIATAAAAAGGCTAAGICACII CTCCACGTTAACCAACTCAGACCTCCTCAACCACTTCGGACCCCCCAGTAACTCTGAGAGTACACGTCGGAGACCTAAGTGAAAGTCACGGATGCGGT S < A · D S ى တ < z < z z ഗ 357 Figure 23 Z ITTTACGGTAACGGTGTCTGGGGCCAGGGGACCCTGGTCACCGTCAGCTCAGCCAAA AAAATGCCATTGCCACAGACCCCGGTCCCCTGGGACCAGTGGCAGTCGAGTCGGTTT 0 ഗ S <u>ح</u> BlpI S ت ی ی _ 3 ليا ی S 9 ری مـ S ⋖ ш 0 ی <u>~</u> z

3

z

Σ

 α

I 9IM

ى

O

```
Sō
                                                                                                                                                       3Ô
                                                    Ō
                                                                                       AGTCGCCGTCACCTAGTCCCTGTCTAAAGTGTGACTTTTAGTCGTCTCACCTCCGACTCCTACAACCTCAAATAATAACGACCGTTCCATGTGAAAAGG
                                                                                                                                        TCAGCGGCAGTGGATCAGGGACAGATTTCACACTGAAATCAGCAGAGTGGAGGCTGAGGATGTTGGAGTTTATTGCTGGCAAGGTACACATTTTCC
                                                   G
                                                                                                                                                                                   0
                                                                                                                                 ഗ
                                                                                                                                                                                   3
                                                                                                                                 0
                                                                               S
                                                                             S
                                                                             ⋖
                                                                                                                                                                                 ⋖
                                                                            ٩
                                                                                                                              ~
                                                                            0
                                                                                                                              <u>~</u>
                                                                                                                                                                                \alpha
                                                                                                                                                                                                                                GTACACGTTCGGACAAGGGACCCGACTGGAAATAAAACGTACGG
                                                                                                                                                                                                                                             CATGTGCAAGCCTGTTCCCTGGGCTGACCTTTATTTTGCATGCC
                                                                                                                                                                               S
                                                                                                                             0
                                                                                                                                                                                             BEIMI
                                                                                                                             ی
                                                                           م
                                                                                                                            <u>~</u>
                                                                           S
                                                                                                                            0
                                                                                                                            O
                                                                                                                                                                              .
_
                                                                           م
                                                                                                                            ш.
                                                                           S
                                                                                                                            Š
                                                                                                                                                                              5
                                                                                                                            z
                                                                                                                                                                              S
                                                                                                                                                                              ى
                                                                                                                                                                             S
                                                                                                                                                                             S
                                                                                                                           ¥
                                                                                                                                                                             S
I Ban2
```

1855.1052-028

Title: Humanized Anti-CCR2 Antibodies...

Gregory J. LaRosa, et al.

Docket No.:

Inventors: